Scientist / Manager Scientist

Gang Wei

*** ******** **.

Wynnewood, PA *****

Phone: 610-***-**** (home)

E-mail: y1h5bb@r.postjobfree.com

OBJECTIVE

A challenging position that allows me to creatively use my diverse skills in clinical oncology and cancer research.

SUMMARY

Unusual amount of clinical oncology experience in Cancer center of Tianjin Medical University and Oncological Surgery Dept. of Hokkaido University. Past positions include resident, chief resident, fellow, attending physician. Solid experience coordinating and managing a wide range of projects in fast-paced environments.

Over 10 years of molecular and cell biology research experience in academia and government. Specialist in oncology, cell signaling, target identification, new cancer therapeutic development, translation research and cancer biomarkers.

Exceptional written, verbal, interpersonal, and team skills.

Proven ability to work with scientists and non-scientists from multiple disciplines and at multiple levels.

An energetic self-starter, who thrives in an innovative, results-focused environment.

International experience includes living and working in the USA, Japan and China. Strong desire to learn new languages. Willing and able to travel.

EDUCATION

Ph.D. Molecular & Cellular Biology, Hokkaido University, Sapporo, Japan

.Dissertation: “Isolation a novel human cancer-testis gene”

MD Tianjin Medical University, Tianjin, China.

AWARDS

Elected Vice-President, Association of Chinese students and scholars in Hokkaido (1997-1999)

Scholarship of Japanese Government (Monbukagakusho) (1996-2000)

Hokkaido Medical Award, 2001.

EMPLOYMENT

2010- present Instructor, Medical Oncology & Cancer Biology Dept. Thomas Jefferson University, PA

2008-2010 Clinical research scientist, Medical Oncology & Cancer Biology Dept. Thomas Jefferson University, PA

Responsibilities

1) screened new compounds, designed new combination therapy for cancer and conducted studies to elucidate the mechanisms of action of novel drug targets in cancer cells.

2) generated animal model of cancer to test new combination therapy in vivo

3) designed protocol for pre-clinical and clinical trial

4) collaborated with industry partners to develop cancer biomarkers for clinical trials use.

5) applied NIH and other external grant, prepared regular reports; wrote chapter of final report to the National Institute of Health (NIH) and submitted paper for publication

6) supervised graduate students and trained lab technicians, residents

2004 – 2008 Post-doctoral Fellow, Lankenau Medical Research Center, Wynnewood, PA.

Responsibilities

1) generated polyamine/ras double transgenic skin tumor mouse model and clarified the mechanisms of polyamine carcinogenesis

2) screened new compound which can inhibit tumor growth in vivo

3) analyzed the potential mechanisms and pathways of polyamine inhibitor

4) assisted NIH grant application, prepared regular reports; wrote chapter of final report to the National Institute of Health (NIH) and submitted paper for publication

5) trained lab assistants and supervised rotation students and residents

2000 – 2004 Post-doctoral Researcher, University of California Riverside, Riverside, CA.

Responsibilities

1) studied the transcription/translation of oncogene and tumor suppressor gene.

2) First found cross talk between oncogene and tumor suppressor gene in signal transductional pathway and develop potential therapeutic targets

3) explored epigenetic modifications of tumor suppressor gene p53 on cancer cell growth

4) prepared regular reports and submitted paper for publication.

5) maintained lab instruments and wrote most protocols and technical documents for team

1996 – 2000 Research Associate, Cancer Institute of University of Hokkaido, Sapporo, Japan.

Responsibilities

1) clarified the mechanism of GC rich factor transcription/ translation in cancer

2) isolated a new human cancer related gene, aiding in future anti-cancer drug development.

1995 – 1996 Senior Clinical Fellow, Dept. of Surgical Oncology , University of Hokkaido, Sapporo, Japan

Responsibilities

1) performed patient care and education,

2) made daily rounds and diagnostics of over 60 case

3) assisted to establish new cancer cell lines for evaluating anti-tumor efficacy

4) collected different cancer samples for experiments and tissue bank

1988 – 1995 Resident , Fellow and attending physician, Dept. Surgical Oncology, Tianjin Medical University, Tianjin, China

Responsibilities

1) performed patient care and education

2) worked in surgical oncology with Medical Staff and collected different cancer samples for experiments and cancer tissue bank

3) promoted health in the hospital via division and research of different diseases

4) collaborated with industry partners to develop cancer for clinical trials

5) made daily rounds, charted and documented activities that may promote health in the hospital

6) Supervised fellow physicians and nurses

SKILLS

Excellent advanced skills in molecular cancer biology research, including in vitro and in vivo, experienced therapeutic development and clinical trial

Proficient in WordPerfect, Windows MS Word, Excel, Power Point, and various application programs

Management Skills: time management, goal settings training, assertiveness training

Strong communications skills as author, lecturer

CERTIFICATE

United States Medical Licensing Examination (USMLE): 2009

ECFMG (Educational Commission for Foreign Medical Graduates) certificate

Certified General Surgeron and Oncologist (China)

LANGUAGES

English, Chinese, Japanese.

RESIDENCY STATUS

Green card

PUBLICATIONS

Brian I. Carr, Ziqiu Wang and Gang Wei. A phase I/II study of vitamin K1 therapy for unresectable HCC and possible mechanisms of action (In press)

Gang Wei, Brian I. Carr, Ziqiu Wang Meifung Wang,. Vitamin K enhances sorafenib effects on HCC in vitro and in vivo: (Int J Cancer. 2010 Jun 7)

Gang Wei, Meifang Wang, Brain I. Carr. Sorafenib combined vitamin k1 induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways. J Cell Physiol. 2010 Jul;224(1):112-9

Gang Wei, Karen DeFeo, Candace S. Hayes, Laura Mandik-Nayak, and Susan K. Gilmour. Elevated Polyamine Biosynthesis Activates ATM - DNA Damage Signaling Pathway and Apoptosis in Normal Keratinocytes. Cancer Res. 2008 Apr 1;68(7):2214-22

Gang Wei*, Cheryl A. Hobbs*, Karen DeFeo, Candace S. Hayes, and Susan K. Gilmour. Polyamine-Mediated Regulation of Protein Acetylation in Murine Skin and Tumors. Mol Carcinog 46: 611-617. (2007).

Hobbs CA, Wei G, Defeo K, Paul B, Hayes CS, Gilmour SK. Tip60 Protein Isoforms and Altered Function in Skin and Tumors that Overexpress Ornithine Decarboxylase. Cancer Res. 2006 Aug 15; 66(16):8116-22.

Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell. 2006 Aug; 23(4):575-87.

Maeda Y, Hwang-Verslues WW, Wei G, Fukazawa T, Durbin ML, Owen LB, Liu X, Sladek FM. Tumour suppressor p53 down-regulates the expression of the human hepatocyte nuclear factor 4alpha (HNF4alpha) gene. Biochem J. 2006 Dec 1; 400(2):303-13.

Piluso LG, Wei G, Li AG, Liu X. Purification of acetyl-p53 using p300 co-infection and the baculovirus expression system. Protein Expr Purif. 2005 Apr; 40(2):370-8.

Gang Wei, Andrew G Li, Xuan Liu. Insights into selective activation of p53 DNA binding by c-Abl . J Biol Chem. 2005 Jan 20.

Sasao T, Itoh N, Takano H, Watanabe S, Wei G, Tsukamoto T, Kuzumaki N, Takimoto M. The protein encoded by cancer/testis gene D40/AF15q14 is localized in spermatocytes, acrosomes of spermatids and ejaculated spermatozoa. Reproduction. 2004 Dec; 128(6):709-16.

Gang Wei, Guoxia Liu and Xuan Liu _Mutagenesis study identifies two serine residues important for p53 DNA binding and protein stablization. FEBS Lett. 2003 May 22; 543(1-3):16-20.

Daniel J. Freeman*, Andrew G. Li*, Gang Wei, Heng-Hong Li, Nathalie_Kertesz, Ralf Lesche, Andrew D. Whale, Hilda Martinez-Diaz, Nora Rozengurt, Robert D. Cardiff, Xuan Liu, and Hong Wu. PTEN tumor suppressor regulates p53 function through phosphates-dependent and independent mechnisms. Cancer Cell 3(2), 117-130, 2003.

Yutaka Maeda, Shawn D. Seidel, Gang Wei, Xuan Liu and Frances M. Sladek _Repression of Hepatocyte Nuclear Factor 4a by Tumor Suppressor p53: Involvement of the Ligand-binding Domain and Histone Deacetylase Activity. Molecular Endocrinology 16(2); 402-410, 2002.

Takimoto M*, Wei G*, Dosaka-Akita H, Mao P, Kondo S, Sakuragi N, Chiba I, Miura T, Itoh N, Sasao T, Koya RC, Tsukamoto T, Fujimoto S, Katoh H, Kuzumaki N. Frequent Expression of New Cancer-testis Gene D40/AF15q14 in Lung Cancer of Smokers. British J. of Cancer. 2002 Jun 5 86(11): 1757-62.

Wei G. Cloning and characterization of a novel human cancer/testis-associated gene. Hokkaido Igaku Zasshi. 2001 Jul; 76(4):203-13.

Takimoto M*, Mao P*, Wei G, Yamazaki H, Miura T, Johnson AC, Kuzumaki N. Molecular Analysis of The GCF Gene Identifies Revisions to the cDNA and Amino Acid Sequences Biochimica et Biophysica Acta 1447:125-131, 1999.

Gang Wei, Masato Takimoto, Ikuya Yoshida, Pei-Zhong Mao, Richard C. Koya, Tetsuya Miura and Noboru Kuzumaki _Chromosomal assignment of a novel human gene D40 Nucleic Acids Symposium 42: 71, 1999.

Masato Takimoto, Gang Wei, Pei-Zhong Mao, Richard C. Koya, Tetsuya Miura and Noboru Kuzumaki. Isolation of cDNAs that cover the entire coding region of a novel human protein D40_ Nucleic Acids Symposium 42:69, 1999.

Masato Takimoto, Gang Wei, Pei-Zhong Mao, Richard C. Koya, Tetsuya Miura and Noboru Kuzumaki Molecular cloning of a novel human protein that binds specifically to nuclear factor GCF. Nucleic Acids Symposium 39:201, 1998.

Detai-Wu, Gang Wei. Electrochemistrytherapy of Malignant Tumor. Chinese Journal of Clinical Oncology 1993, 20 (4).

Zhenqin Zhao, Gang Wei. Primary Malignant Fibrous Historytoma of Lung. Chinese Journal of Clinical Oncology 1993, 20 (5).

Zhenqin Zhao, Gang Wei. The Causes of Exploration on Esophageal Cancer. Chinese Journal of Clinical Oncology 1993, 20 (12).

Qingwen Jin, Gang Wei. Total Gastrectomy of Cardiac Carcinoma. Chinese Journal of Clinical Oncology 1994, 21 (6).

* denotes equal contribution

Contact this candidate